Arvinas Competitors and Similar CompaniesClear all

Foghorn Therapeutics's competitors and similar companies include Lyell, Agenus and Elicio Therapeutics.
Foghorn Therapeutics
Foghorn Therapeutics
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
Lyell
Lyell
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.
Agenus
Agenus
Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer.
Elicio Therapeutics
Elicio Therapeutics
Elicio Therapeutics (formerly known as Vedantra Pharmaceuticals) is an immuno-oncology company developing vaccines and immunotherapies for aggressive solid and hematologic cancers.
Founding Date
Founding Date
2016
Founding Date
2018
Founding Date
1994
Founding Date
2011
Type
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Cambridge, US
Locations
South San Francisco, US HQ
Bothell, US
Seattle, US
Locations
Lexington, US HQ
Cambridge, GB
Berkeley, US
New York, US
Locations
Cambridge, US HQ
Employees
Employees
16135% increase
Employees
188
Employees
32812% increase
Employees
22
Valuation ($)
Valuation ($)
183.6 m
Valuation ($)
420.6 m
Valuation ($)
268.6 m
Valuation ($)
47.2 m
Twitter followers
Twitter followers
1.1 k
Twitter followers
N/A
Twitter followers
2.5 k
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
9
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
8
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
2.3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
13.4
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
88.89%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Employee Rating
Employee Rating
4.2
Employee Rating
3.4
Employee Rating
3.2
Employee Rating
5

Financial

Revenue (est.)
Revenue (est.)
$19.2m (FY, 2022)
Revenue (est.)
$84.7m (FY, 2022)
Revenue (est.)
$98m (FY, 2022)
Revenue (est.)
$2.3m (FY, 2022)
Net income
Net income
($108.9m) (FY, 2022)
Net income
($183.1m) (FY, 2022)
Net income
($230.7m) (FY, 2022)
Net income
($38.8m) (FY, 2022)

Funding

Total funding raised
Total funding raised
$ 50m
Total funding raised
N/A
Total funding raised
$ 171.1m
Total funding raised
$ 150.3m
For sources of this data, please see the company profile

View Company Profiles

Lyell
HQ
South San Francisco, US
Employees
188

Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.

View company
Agenus
HQ
Lexington, US
Employees
328↑ 12% increase

Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer.

View company
Elicio Therapeutics
HQ
Cambridge, US
Employees
22

Elicio Therapeutics (formerly known as Vedantra Pharmaceuticals) is an immuno-oncology company developing vaccines and immunotherapies for aggressive solid and hematologic cancers.

View company